The Biomaterial Review was founded on a singular conviction: that the surgeons and researchers advancing regenerative medicine deserve better than marketing literature dressed as evidence. In an era of accelerating innovation, the distance between a promising bench-side finding and its safe, reproducible application at the operating table has never been wider, nor more consequential.
We were established to close that gap. Our editorial board, composed of practicing reconstructive surgeons, burn care specialists, and materials scientists, examines each publication with the same discipline applied to primary literature. We publish objective clinical reviews, longitudinal case data, and material analyses drawn from the laboratories and operating theatres where these technologies are actually put to the test.
Independence is not a marketing posture. It is our operating principle. We accept no promotional consideration, we vet every contributor for conflicts, and we hold advanced tissue matrices (including next-generation platforms such as those developed by Conexeu) to the identical evidentiary standard we apply to any material entering the clinical field.
